Traditional Chinese medicine therapy decreases the pneumonia risk in patients with dementia

Lin, Shun‐Ku; Tsai, Yi Yu; Lo, Pei-Chia

doi:10.1097/md.0000000000004917

Cited by 22 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, traditional Chinese herbs may be helpful for remedying biased TCMCs and certain specific diseases. [ 29 , 30 ] One example is an antimalarial substance extracted from a plant using a low-temperature process that was discovered by the researcher Tu Youyou, [ 31 ] who received the 2015 Nobel Prize in Physiology or Medicine for her work. In a word, TCMC may be a useful and simple classification system to predict the risk of hypertension and determine preventive and therapeutic effects.…”

Section: Discussionmentioning

confidence: 99%

Individualized prevention against hypertension based on Traditional Chinese Medicine Constitution Theory

Liu

Huang

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Individualized prevention against hypertension based on Traditional Chinese Medicine Constitution Theory

Liu

Huang

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Recently, anti‐inflammatory management has become a key to the clinical remediation of neonatal pneumonia. The current study has shown that TCM therapy achieved a good curative effect in clinical application for pneumonia . Nevertheless, whether NGR1 can be applied for healing neonatal pneumonia is still unclear.…”

Section: Discussionmentioning

confidence: 83%

Retracted: Notoginsenoside R1 protects WI‐38 cells against lipopolysaccharide‐triggered injury via adjusting the miR‐181a/TLR4 axis

Qian

Shao

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Notoginsenoside R1 (NGR1) is a neoteric phytoestrogen extracted from Panax notoginseng, and possesses comprehensive pharmacological functions in multitudinous ailments. But, whether NGR1 is utilized in neonatal pneumonia is not clear. This research study aspired to disclose the protective activity of NGR1 in neonatal pneumonia. WI-38 cells were co-stimulated with NGR1 and lipopolysaccharide (LPS, 10 ng/mL), CCK-8 and flow cytometry assays were implemented for cell viability and apoptosis assessment. Real-time quantitative plymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and Western blot analysis were executed for inflammatory cytokine determination. MicroRNA-181a (miR-181a) expression was evaluated through RT-qPCR, simultaneously, the impact of miR-181a was estimated in NGR1 and LPS co-managed cells. Dual luciferase report assay was performed to disclose the relation between miR-181a and Toll-like receptor 4 (TLR4). The nuclear factor-κB (NF-κB) and TAK1/JNK pathways were ultimately appraised.We found that NGR1 decreased cell viability, evoked apoptosis and impeded interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) expression and secretions in LPS-managed WI-38 cells. MiR-181a expression was enhanced by NGR1, and miR-181a inhibition inverted the impacts of NGR1 in LPSmanaged WI-38 cells. Besides, TLR4 was predicted to be a firsthand direct target of miR-181a. Furthermore, NGR1 hindered NF-κB and TAK1/JNK pathways through modulating TLR4. These discoveries disclosed the fact that NGR1 protected WI-38 cells against LPS-triggered injury via adjusting the miR-181a/ TLR4 and NF-κB and TAK1/JNK pathways. K E Y W O R D SmicroRNA-181a, neonatal pneumonia, NF-κB, notoginsenoside R1, TAK1/JNK, toll-like receptor 4 | INTRODUCTIONNeonatal pneumonia is a universal ailment among newborns, and is also a major reason for neonatal death. 1 Statistical evidence displays that about 156 million new events of neonatal pneumonia take place around the world each year, and 95% of neonatal pneumonia episodes happen in the developing countries. 2 The clinical manifestations of neonatal pneumonia comprise fever, cough, dyspnea, heart failure, sepsis, and even death. 3,4 The causes of neonatal pneumonia are multitudinous and are linked to malnutrition, unsafe sanitation,

show abstract

“…Ephedrine, amygdalin, ephedrine, glycyrrhizic acid, and amygdalin are considered as the main active components (Wang et al, 2016). A series of clinical studies have shown that MXGST is widely used in the treatment of cough, asthma, pneumonia, COPD, and other diseases (Chen et al, 2013;Wang et al, 2014;Lin S. K. et al, 2016;Liao et al, 2017). In an animal experimental study, Lin et al adopted citric acid-induced cough in guinea pigs cough model to study the pharmacological effect of MXGST water extract in clinical application, and evaluated its subacute toxicity, and found that MXGST water extract (0.4, 1.0 g/kg) has a significant dose-dependent antitussive effect on guinea pigs, which is a safe and effective traditional Chinese medicine prescription .…”

Section: Chinese Patent Medicinementioning

confidence: 99%

Research Progress on Main Symptoms of Novel Coronavirus Pneumonia Improved by Traditional Chinese Medicine

Luo

Liu

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Novel coronavirus (COVID-19) pneumonia has become a major threat to worldwide public health, having rapidly spread to more than 180 countries and infecting over 1.6 billion people. Fever, cough, and fatigue are the most common initial symptoms of COVID-19, while some patients experience diarrhea rather than fever in the early stage. Many herbal medicine and Chinese patent medicine can significantly improve these symptoms, cure the patients experiencing a mild 22form of the illness, reduce the rate of transition from mild to severe disease, and reduce mortality. Therefore, this paper summarizes the physiopathological mechanisms of fever, cough, fatigue and diarrhea, and introduces Chinese herbal medicines (Ephedrae Herba, Gypsum Fibrosum, Glycyrrhizae Radix et Rhizoma, Asteris Radix et Rhizoma, Ginseng Radix et Rhizoma, Codonopsis Radix, Atractylodis Rhizoma, etc.) and Chinese patent medicines (Shuang-huang-lian, Ma-xinggan-shi-tang, etc.) with their corresponding therapeutic effects. Emphasis was placed on their material basis, mechanism of action, and clinical research. Most of these medicines possess the pharmacological activities of anti-inflammatory, antioxidant, antiviral, and immunity-enhancement, and may be promising medicines for the treatment or adjuvant treatment of COVID-19 patients.

show abstract

Traditional Chinese medicine therapy decreases the pneumonia risk in patients with dementia

Abstract: Supplemental Digital Content is available in the text

Cited by 22 publications

References 37 publications

Individualized prevention against hypertension based on Traditional Chinese Medicine Constitution Theory

Individualized prevention against hypertension based on Traditional Chinese Medicine Constitution Theory

Retracted: Notoginsenoside R1 protects WI‐38 cells against lipopolysaccharide‐triggered injury via adjusting the miR‐181a/TLR4 axis

Research Progress on Main Symptoms of Novel Coronavirus Pneumonia Improved by Traditional Chinese Medicine

Contact Info

Product

Resources

About